巴西前瞻性注册研究:Inspiron EVO药物洗脱支架在复杂冠状动脉病变中的应用 (PCI EVOlution)
国家前瞻性Inspiron EVO药物洗脱支架在复杂冠状动脉病变中的登记注册
The objective is to evaluate the efficacy and safety of the Inspiron™ EVO drug-eluting stent in complex coronary lesions in a real-world population. Patients with symptomatic ischemic heart disease due to lesions in native coronary arteries and restenotic lesions will be treated with the Inspiron™ EVO drug-eluting stent.
研究概览
地位
详细说明
Post-marketing, observational, prospective, multi-center, non-randomized, single-arm registry that will include all patients who receive the Inspiron™ EVO stent at participating sites and meet the eligibility criteria.
Up to 2,000 patients are expected to be enrolled across 12 research sites in Brazil. Participants' demographic, procedural, and follow-up data will be collected for up to 12 months in this study.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Marco Aurélio A Costa, MD, PhD
- 电话号码:+1 216 903-9327
- 邮箱:marco.costa@scitechmed.com
研究联系人备份
- 姓名:Ana Paula B Pellaquim, MSc.
- 电话号码:+55 62 9471-4439
- 邮箱:aalmeida@scitechmed.com
学习地点
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、巴西、90610000
- 招聘中
- Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)
-
接触:
- Paulo Ricardo A Caramori, MD
- 电话号码:+55 51 99982 0766
- 邮箱:caramori@cardiarte.com.br
-
接触:
- Rosa Homem
- 电话号码:+55 51 99679 8040
- 邮箱:cer.pesquisaclinica@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients with symptomatic ischemic heart disease due to lesions in native coronary arteries and restenotic lesions treated with the Inspiron™ EVO Drug-Eluting Stent.
描述
Inclusion Criteria:
- Individuals aged 18 years or older presenting with complex coronary lesions requiring percutaneous coronary intervention (PCI).
- Individuals who provide consent and are willing to comply with the follow-up protocol.
- Individuals who received treatment with the Inspiron™ EVO Stent.
- Individuals with lesions ≥ 30 mm in length (Subprotocol 1).
- Individuals with significantly calcified coronary lesions (moderate to severe according to the ACC/AHA classification B1, B2, or C), with or without indication for lesion preparation techniques (Subprotocol 2).
- Individuals with multivessel coronary artery disease (≥2 affected coronary vessels, with at least one vessel of small diameter ≤2.5 mm) (Subprotocol 3).
- Individuals included in Subprotocol 1, 2, or 3. The evaluated segment must be accessible to the IVUS (Intravascular Ultrasound) catheter (Subprotocol 4).
Exclusion Criteria:
- Lesions in saphenous vein grafts or internal mammary grafts.
- Contraindication to the use of a drug-eluting stent.
- Individuals who were treated during the index procedure with any stent other than the Inspiron™ EVO Stent.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Experimental: Percutaneous coronary intervention (PCI)
Patients with symptomatic ischemic heart disease due to lesions in the native coronary artery and restenotic lesions treated with the Inspiron™ EVO drug-eluting stent. |
Percutaneous coronary intervention (PCI) using the Inspiron EVO Drug-Eluting Stent, which has a reduced crimped profile, providing greater safety and facilitating lesion crossing. In addition, the design is optimized to provide increased radial strength. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Device success
大体时间:Initial procedure
|
Device success (at the lesion level) is defined as the successful delivery, balloon expansion, and implantation of the first device at the target lesion (with multiple attempts using the same device permitted), successful withdrawal of the delivery system, and achievement of a final in-stent residual stenosis of <20% |
Initial procedure
|
|
Acute Clinical Success of Percutaneous Coronary Intervention (PCI)
大体时间:Up to 24 hours
|
Defined as the absence of major adverse in-hospital cardiac events (death, myocardial infarction, or repeat coronary revascularization of the target lesion). |
Up to 24 hours
|
|
MACE (Major Adverse Cardiac Events) rate
大体时间:12 months
|
Defined as the combination of cardiac death, myocardial infarction (MI), or revascularization of the target lesion (TLR). |
12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Target Lesion Revascularization (TLR) rate
大体时间:12 months
|
TLR is defined as any percutaneous reintervention of the target lesion, including the 5 mm proximal and 5 mm distal segments of the stent, or revascularization of the target vessel, performed for clinical reasons due to restenosis or occlusion of the target lesion. |
12 months
|
|
Target vessel revascularization rate (TVR)
大体时间:12 months
|
TVR is defined as revascularization of any segment of the target coronary artery. |
12 months
|
|
Target Vessel Failure Rate (TVF)
大体时间:12 months
|
Defined as a combination of MI, TLR, or cardiovascular death related to the target vessel. If it is not possible to determine with certainty whether the MI or death was related to the target vessel, the case is considered a TVF. |
12 months
|
|
Rate of definite, probable, and possible stent thrombosis (ST)
大体时间:12 months
|
Stent thrombosis is classified as definite, probable, or possible: definite requires angiographic or pathological confirmation; probable includes unexplained death within 30 days or myocardial infarction related to the stented territory without angiographic confirmation; and possible refers to any unexplained death occurring from 30 days after implantation until the end of follow-up. |
12 months
|
|
Cardiovascular mortality
大体时间:12 months
|
Any death due to an immediate cardiac cause (e.g., myocardial infarction, low-output heart failure, fatal arrhythmia), unwitnessed death, death of unknown cause, and all procedure-related deaths, including those related to concomitant treatment, will be classified as cardiac death. |
12 months
|
|
Late in-segment luminal loss (including the in-stent portion and the 5-mm proximal and distal edges)
大体时间:6 months
|
Defined as the difference between the in-segment minimum luminal diameter (MLD) (including the in-stent portion and the 5-mm proximal and distal edges) after the procedure and the MLD at the 6-month follow-up, as determined by quantitative angiography. |
6 months
|
|
Percent Area Stenosis (%AS)
大体时间:6 months
|
Defined as the ratio between the neointimal hyperplasia area and the stent area multiplied by 100 at the 6-month follow-up. |
6 months
|
合作者和调查者
调查人员
- 首席研究员:Paulo Ricardo A Caramori, MD、Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.